间皮素作为癌症免疫治疗的生物标志物和治疗靶点
Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer.
癌症仍是一个关键的全球健康问题,原因在于发现晚、耐药和高死亡率。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:PIK3CA mutation subtype delineates distinct immune profiles in gastric carcinoma.
PIK3CA mutation subtype delineates distinct immune profiles in gastric carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
癌症中的PIK3CA突变调控肿瘤免疫原性。鉴于PIK3CA突变亚型影响对AKT抑制剂的治疗反应,且H1047R突变在免疫治疗后赋予选择性生长优势,我们假设免疫表型可能取决于PIK3CA突变亚型。
我们研究了133例携带PIK3CA突变的胃癌(GC)[21例E542K(15.8%)、36例E545X(27.1%)、26例H1047X(19.5%)和46例其他(34.6%)]。4例患者(3.0%)存在突变组合(3例为E542K + E545K,1例为E545K + H1047R)。评估了Epstein-Barr病毒(EBV)和微卫星不稳定性(MSI)状态、PD-L1(程序性死亡配体1)联合阳性评分(CPS)以及间质TIL(肿瘤浸润淋巴细胞)(TILs)。分析了同期基因组改变、GeoMx数字空间分析(DSP)和OPAL多重免疫组化(mIHC),并研究了两种检测方法之间的相关性。在133例PIK3CA突变(PIK3CA m)GC中,MSI-high GC在H1047X突变亚型中显著频繁(p = 0.005),而EBV阳性不影响突变亚型。E542K、E545X和H1047X亚组之间无显著生存差异。
然而,在EBV阳性GC的亚组分析中,H1047X m GC显示出比E542K和E545X m GC生存更短的趋势(p = 0.090和0.062)。通过DSP分析,与E542K m或E545X m GC亚组相比,H1047X m GC显示VISTA(p = 0.0003)、颗粒酶B(p < 0.0001)、CD4(p = 0.0001)和CD45(p < 0.0001)表达升高,而使用OPAL mIHC仅VISTA表达仍显著(p < 0.0001)。DSP和OPAL分析显示CD4(ρ = 0.42,p = 0.004)和CD8(ρ = 0.62,p < 0.001) 在六种抗体的比较中的表达水平。当按三种 PIK3CA 热点突变分类时,免疫相关蛋白表达水平明显不同,与 E542K m 或 E545X m GC 相比,H1047X m GC 显示出最高的免疫相关蛋白表达。
我们的结果使用 GeoMx DSP 和 OPAL mIHC 证明了具有 PIK3CA 热点突变的 GC 中存在不同的免疫特征,并且两种多重平台之间存在相关性。© 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
PIK3CA mutations in cancer regulate tumour immunogenicity. Given that PIK3CA mutation subtypes influence therapeutic responses to AKT inhibitor and that H1047R mutation confers selective growth advantages after immunotherapy, we hypothesised that immune phenotypes may depend on PIK3CA mutation subtypes.
We investigated 133 gastric cancers (GCs) harbouring PIK3CA mutation [21 E542K (15. 8%), 36 E545X (27. 1%), 26 H1047X (19. 5%), and 46 others (34. 6%)]. Four patients (3. 0%) had a combination of mutations (E542K + E545K in 3 patients and E545K + H1047R in 1 patient). Epstein-Barr virus (EBV) and microsatellite instability (MSI) status, PD-L1 (programmed death-ligand 1) combined positive score (CPS), and stromal tumour-infiltrating lymphocytes (TILs) were assessed.
Concurrent genomic alterations, GeoMx digital spatial profiling (DSP), and OPAL multiplex immunohistochemistry (mIHC) were analysed, and correlation between the two assays was investigated. Of the 133 PIK3CA-mutant (PIK3CA m ) GCs, MSI-high GC was significantly frequent in the H1047X mutation subtype (p = 0. 005), while EBV positivity did not affect the mutation subtypes. There was no significant survival difference between the E542K, E545X, and H1047X subgroups.
However, in the subgroup analysis for EBV-positive GC, H1047X m GC showed a trend towards shorter survival than E542K and E545X m GC (p = 0. 090 and 0. 062). With DSP analysis, H1047X m GC showed elevated VISTA (p = 0. 0003), granzyme B (p < 0. 0001), CD4 (p = 0. 0001), and CD45 (p < 0. 0001) expression compared with the E542K m or E545X m GC subgroups, and only VISTA expression remained significant (p < 0.
0001) using OPAL mIHC. DSP and OPAL analyses showed a moderate correlation of CD4 (ρ = 0. 42, p = 0. 004) and CD8 (ρ = 0. 62, p < 0. 001) expression levels in a comparison of six antibodies. Immune-related protein expression levels were evident when classified by the three PIK3CA hotspot mutations, and H1047X m GC showed the highest immune-related protein expression compared with E542K m or E545X m GC.
Our results demonstrated distinct immune profiles in GC with PIK3CA hotspot mutations using GeoMx DSP and OPAL mIHC, and there was a correlation between the two multiplex platforms. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
MEMBER ACCOUNT
登录成功会直接打开下一页。